This content is from: Research

Health Care: Biotechnology 2010 Third

Geoffrey Porges of Sanford C. Bernstein & Co., who lands in third place for a third consecutive year, does “great contrarian valuation work,” declares one portfolio manager.

Geoffrey Porges

Sanford C. Bernstein & Co.

Geoffrey Porges of Sanford C. Bernstein & Co., who lands in third place for a third consecutive year, does “great contrarian valuation work,” declares one portfolio manager. When many analysts concluded in July 2009 that shares of Rockville, Maryland–based Human Genome Sciences were fully valued at $12.51, Porges argued that the stock had plenty of room left to run. Boy, did it. The share price had catapulted 132.4 percent, to $29.07, by the end of August 2010.

Related Content